Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Recursion Pharmaceuticals, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Recursion Pharmaceuticals held its 2026 annual stockholder meeting on June 17, 2026, where shareholders elected two Class II directors: Najat Khan, Ph.D. and Franziska Michor, Ph.D., to serve until 2029. This routine governance event demonstrates strong shareholder engagement and confirms the company's board composition.
Key Takeaways
Najat Khan, Ph.D. was elected as Class II director with 210,437,751 votes in favor and 27,907,256 votes withheld
Franziska Michor, Ph.D. was elected as Class II director with 208,124,737 votes in favor and 30,220,270 votes against
2 more takeaways